KARD (Kardigan) EV-to-EBIT: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.46
! 1 Warning Sign
View Full Analysis

What is Kardigan EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kardigan's Enterprise Value is $1,554.69 Mil. Kardigan does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kardigan's EV-to-EBIT at this moment.

The historical rank and industry rank for Kardigan's EV-to-EBIT or its related term are showing as below:

KARD' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.76   Med: 0   Max: 0
Current: -7.7
KARD's EV-to-EBIT is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 12.71 vs KARD: -7.70

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kardigan's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. Kardigan does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Kardigan's Earnings Yield (Joel Greenblatt) % at this moment.

Kardigan  (NAS:KARD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Kardigan's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

Kardigan EV-to-EBIT Related Terms

Kardigan EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Kardigan's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan EV-to-EBIT Chart

Kardigan Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

Kardigan Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

KARD vs OCUL, GHRS, FTRE: EV-to-EBIT Comparison

For the Biotechnology subindustry, Kardigan's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kardigan EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kardigan's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kardigan's EV-to-EBIT falls into.


KARD
11GF Score
Kardigan Inc KARD
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan EV-to-EBIT Calculation

Kardigan's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1554.685/
=

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.46
Price